搜尋
Vyne Therapeutics Inc
VYNE添加自選
0.681USD
+0.030+4.66%
收盤 07/01, 16:00（美東）報價延遲15分鐘
22.71M總市值
虧損本益比TTM
關鍵數據
0.650今開
0.695最高
692.53K成交量
虧損本益比TTM
虧損本益比動
--股利TTM
2.08%換手率
0.651昨收
0.650最低
382.17K成交額
虧損本益比靜
0.92市淨率
0.00%股息率 TTM
-52.78%ROA
1.96052週最高
6.11量比
-39.83M淨利潤
33.35M總股本
-0.5012每股盈餘TTM
2.01Beta
-63.16%ROE
0.28152週最低
6.90%振幅
100.00%毛利率
22.71M總市值
-0.90回報/風險
4.18%風險率
TradingKey Vyne Therapeutics Inc股票評分
單位: USD 更新時間: 2026-06-30操作建議
Vyne Therapeutics Inc當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名206/387位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為2.00。中期看，股價處於平穩狀態。近一個月，市場表現一般，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Vyne Therapeutics Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
看好
Vyne Therapeutics Inc亮點
亮點風險
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
業績高增長
公司營業收入穩步增長，連續3年增長34.43%
業績增長期
公司處於發展階段，最新年度總收入570.00K美元
估值低估
公司最新PE估值-1.30，處於3年歷史低位
機構減倉
最新機構持股11.08M股，環比減少13.12%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉15.19K股
分析師目標
基於
2
分析師
買入
評級
2.000
目標均價
+207.36%
漲幅空間
Vyne Therapeutics Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Vyne Therapeutics Inc簡介
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
公司代碼VYNE
公司Vyne Therapeutics Inc
CEODomzalski (David)
網址https://vynetherapeutics.com/
相關品種
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%熱門品種
52263.200
+8.900 (+0.02%)
29840.500
+41.200 (+0.14%)
7481.500
+6.000 (+0.08%)
15354.000
-1.000 (-0.01%)
69649.000
+164.000 (+0.24%)
6279.100
+3.700 (+0.06%)
67.934
-0.034 (-0.05%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4039.180
+8.410 (+0.21%)
常見問題
Vyne Therapeutics Inc(VYNE)的當前股價是多少？
Vyne Therapeutics Inc(VYNE)的當前股價是 0.65。
Vyne Therapeutics Inc 的股票代碼是什麼？
Vyne Therapeutics Inc的股票代碼是VYNE。
Vyne Therapeutics Inc股票的52週最高點是多少？
Vyne Therapeutics Inc股票的52週最高點是1.96。
Vyne Therapeutics Inc股票的52週最低點是多少？
Vyne Therapeutics Inc股票的52週最低點是0.28。
Vyne Therapeutics Inc的市值是多少？
Vyne Therapeutics Inc的市值是21.62M。
現在Vyne Therapeutics Inc(VYNE)的股票是買入、持有還是賣出？
根據分析師評級，Vyne Therapeutics Inc(VYNE)的總體評級為買入，目標價格為2.00。
Vyne Therapeutics Inc(VYNE)股票的每股收益（EPS TTM）是多少
Vyne Therapeutics Inc(VYNE)股票的每股收益（EPS TTM）是-0.62。